Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16865198 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL7389926 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2RECQLTSHRCTSSCTSK | |
| SCHEMBL16424010 | 0.78 | ALDH1A1 (0.45) | SMN1; SMN2RECQLTSHRLMNAUSP2 | |
| SCHEMBL16838112 | 0.77 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16433761 | 0.76 | TSHR (0.49) | SMN1; SMN2RECQLTSHRCTSSCTSK | |
| SCHEMBL16424043 | 0.76 | TSHR (0.49) | SMN1; SMN2RECQLTSHRCTSSCTSK | |
| SCHEMBL16433815 | 0.76 | TSHR (0.49) | SMN1; SMN2RECQLTSHRCTSSCTSK | |
| SCHEMBL17885747 | 0.76 | RECQL (0.58) | SMN1; SMN2RECQLTSHRCTSSCTSK | |
| SCHEMBL20083906 | 0.75 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL939255 | 0.75 | CHRNB2 (0.56) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| US-20100063080-A1 | CXCR2 inhibitors | PRESS NEIL JOHN | 2010-03-11 | — | — | US | disclosed |
| WO-2008061740-A1 | PYRIMIDINES AND THEIR USE AS CXCR2 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063080-A1 | CXCR2 inhibitors | CXCR2, CXCR1, CXCR3 | CHRNB2 3741/4885CHRNA3 4341/4885CHRNA4 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.